Medical Communications
MHRA authorises GSK’s RSV vaccine for older adults
July 10, 2023 Medical Communications Arexvy, GSK, Infections and infestations, MHRA, RSV
Celltrion launches Humira biosimilar in US
July 7, 2023 Medical Communications Chronic Diseases, Humira, Yuflyma, arthritis, celltrion
FDA grants Alzheimer’s disease drug Leqembi full approval
July 7, 2023 Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology
Jacobio Pharma receives CDE approval for pancreatic cancer study in China
July 5, 2023 Medical Communications CDE, China, Jacobio Pharma, Oncology, Pancreatic cancer, clinical trial
AstraZeneca shares results from phase 3 trial of datopotamab deruxtecan for NSCLC
July 3, 2023 Medical Communications AstraZeneca, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
FDA approves BioMarin’s Roctavian for adults with severe haemophilia A
June 30, 2023 Medical Communications BioMarin, FDA, Haematology, Roctavian, haemophilia
First cellular therapy for patients with type 1 diabetes approved by FDA
June 29, 2023 Medical Communications Diabetes, FDA, Lantidra, Type 1 diabetes, diabetes
Microba commences phase 1 clinical trial for IBD drug
June 28, 2023 Medical Communications Biotherapeutic, Gastrointestinal tract, Microba, clinical trials, ibd
Astellas Pharma shares positive results from phase 3b trial of Fezolinetant for menopause symptoms
June 28, 2023 Medical Communications Astellas Pharma, Pharmacy, clinical trial, fezolinetant, menopause
Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis
June 28, 2023 Medical Communications Dermatology, NHS, Sotyktu, bristol myers squibb, psoriasis
UK nonprofit National Cancer Research Institute to close
June 27, 2023 Medical Communications Cancer, NCRI, National Cancer Research Institute, Oncology, oncology
AstraZeneca’s Xigduo XR approved in China for adults with type-2 diabetes
June 27, 2023 Medical Communications AstraZeneca, China, Diabetes, Xigduo XR, diabetes
FDA approves Pfizer’s Litfulo for patients with severe alopecia areata
June 26, 2023 Medical Communications FDA, Litfulo, Pfizer, Pharmacy, alopecia, alopecia areata
AstraZeneca’s Soliris given EU CHMP recommendation for marketing authorisation
June 26, 2023 Medical Communications AstraZeneca, CHMP, EMA, Immunology, soliris
CHMP gives positive opinion recommending authorisation to GSK’s CKD drug
June 26, 2023 Medical Communications CKD, EMA, Nephrology
Latest content
Acumentis CEO Herspiegel steps down as Burden assumes role
